Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.
about
Meloxicam prevents COX-2-mediated post-surgical inflammation but not pain following laparotomy in miceMeloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female ratsInduction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activationMerging pathology with biomechanics using CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration): a novel, surgery-free model of traumatic brain injury.Meloxicam ameliorates the cartilage and subchondral bone deterioration in monoiodoacetate-induced rat osteoarthritisIn vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP).Comparative study to investigate the effect of meloxicam or minocycline HCl in situ gel system on local treatment of periodontal pockets.Development and validation of a dissolution test for meloxicam and pridinol mesylate from combined tablet formulationPharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration.Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy.Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea.Effects of buprenorphine, meloxicam, and flunixin meglumine as postoperative analgesia in mice.Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the catGastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled studyEffects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis.Meloxicam in rheumatoid arthritis.Minimising the potential for metabolic activation in drug discovery.Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study.Strong Correlation of Genome-Wide Expression after Traumatic Brain Injury In Vitro and In Vivo Implicates a Role for SORLA.Isoindoline Derivatives of α-Amino Acids as Cyclooxygenase 1 and 2 Inhibitors.Characterization of a rat model of metastatic prostate cancer bone pain.Postoperative Analgesia Due to Sustained-Release Buprenorphine, Sustained-Release Meloxicam, and Carprofen Gel in a Model of Incisional Pain in Rats (Rattus norvegicus).Use of a once-daily NSAID in treatment of cyclic vomiting syndrome.Clinical findings and gingival crevicular fluid prostaglandin E2 and interleukin-1-beta levels following initial periodontal treatment and short-term meloxicam administration.In vitro studies on controlled-release cellulose acetate films for local delivery of chlorhexidine, indomethacin, and meloxicam.In vitro studies of a degradable device for controlled-release of meloxicam.Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors.Acute effects of carprofen and meloxicam on canine gastrointestinal permeability and mucosal absorptive capacity.The effect of mixed-solvent and terpenes on percutaneous absorption of meloxicam gel.Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam.Ion-pair formation combined with a penetration enhancer as a dual strategy to improve the transdermal delivery of meloxicam.Bioequivalence in dogs of a meloxicam formulation administered as a transmucosal oral mist with an orally administered pioneer suspension product.Impact of anaesthetics and analgesics on fetal growth in the mouse.Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia.Effects of intratesticular injection of zinc-based solution in rats in combination with anti-inflammatory and analgesic drugs during chemical sterilization.Physicochemical characterization, the Hirshfeld surface, and biological evaluation of two meloxicam compounding pharmacy samples.COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats
P2860
Q27335431-1A562EDF-40F2-4BE1-9BDB-086F8FBDA833Q28543458-8A9C253E-B55C-4793-B83D-C8BF0510A009Q28578377-E3C11E38-3A48-4D73-8C84-19738D1279D6Q30609157-4CC9C848-022B-465F-AE82-77B0CF945E8DQ33565021-B1A6F3A6-BD8E-4E81-AE04-EFB8661BFB22Q33599019-A59A0836-519E-4104-95D9-A6177D01B992Q33662836-BFAF8D96-9701-40E9-B8D4-D4C4AB7169F9Q33723010-01FF213D-04D5-427C-9967-125059122EB5Q33962520-3470C2B7-80E5-4F97-A3AA-2E0402E9204EQ34090349-98C2BBB3-B26A-4A8C-83C3-194B916FE52CQ34327601-17C6F246-917C-4737-863A-D452DF55CE49Q34521101-AF45F157-4C15-41EF-96A6-3E6B57D5483BQ34548938-0E25D4B2-7081-4070-8599-5A8ADF870773Q34701327-10543E62-63A4-4330-9F02-FA014B7E9077Q35545077-C803AA28-3182-4E5B-98B1-5DF388CCACBAQ35802532-98622FAC-EAAC-4BBA-B9DC-79314DDBC75AQ36107649-24E264DE-139E-437B-8A2B-2272659AEF2AQ36544898-5B07A5C7-F0F4-4972-BCA3-810BCCADD5AAQ36572637-A157B817-4BBF-405C-B4BD-137A83D4D8FBQ38008692-2D76B563-6310-4680-8774-81A3D9322E51Q38885554-A09554E6-2B12-47C6-9E67-244F4A24C2CEQ38902852-276B733B-04D6-43F8-B0A5-221161CA2811Q40113028-47D9EF44-76B0-4F0C-8577-08049A5DEA95Q41244868-0A98DA24-C34A-4B6F-A18E-C95355958E39Q41499919-E9CB5216-3BAC-4A95-99BE-F041CEA20076Q41969465-6F919CB2-61F4-4998-B82A-A6614C7EF946Q43046416-543ED380-3D0D-4233-95D6-E6ECBEA12372Q45160559-C377295C-53F4-4CAA-880F-B1AF84C27432Q46556599-CF5D4A07-B43A-4836-B1B3-B77F518AB033Q46798434-70D99957-BFD0-4A98-923A-EE5F75DFCAC4Q46948330-628DCA76-0905-4FEF-B0EC-1ADB30693CE5Q46984706-32B223F4-E12B-4925-A651-98C04D08F06DQ47752791-636C0D93-2553-487C-B107-9DD01BC72437Q47778654-A57033C6-E8D9-4FD7-9D7A-BC7E2F26A1B1Q47853735-03B639AD-C18A-44E6-8EFC-BA2FA973F1D0Q47999380-F456C203-C0BF-40F3-B83A-174156E637A2Q50928647-8A89ADD6-8376-4A53-BD2A-700CE1CC7EBFQ55330364-65D15BD2-660A-4E9D-993C-EEA054CD2817Q55520941-2DF77283-EFD7-4340-A139-F6BDAF2B9C92Q57219768-9BB92951-BDD2-44A1-8785-5CF20371EB40
P2860
Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Pharmacology of meloxicam, a n ...... ferential inhibition of COX-2.
@en
type
label
Pharmacology of meloxicam, a n ...... ferential inhibition of COX-2.
@en
prefLabel
Pharmacology of meloxicam, a n ...... ferential inhibition of COX-2.
@en
P356
P1476
Pharmacology of meloxicam, a n ...... ferential inhibition of COX-2.
@en
P2093
G Engelhardt
P356
10.1093/RHEUMATOLOGY/35.SUPPL_1.4
P478
35 Suppl 1
P577
1996-04-01T00:00:00Z